RIGL Q4 2022 Earnings — Rigel Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RIGLRigel Pharmaceuticals, Inc.

$541M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$51M+151.3% YoY

Gross Profit

$51M99.3% margin

Operating Income

$2M4.1% margin

Net Income

$1M2.7% margin

EPS (Diluted)

$0.10

QoQ Revenue Growth

+128.8%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$22M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$134M

Total Liabilities

$148M

Stockholders' Equity

-$14M

Cash & Equivalents

$24M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$51M	$20M	+151.3%
Gross Profit	$51M	$20M	+155.7%
Operating Income	$2M	-$21M	+109.7%
Net Income	$1M	-$23M	+106.2%

Revenue Segments

Gross product sales

$33M32%

Contract revenues from collaborations

$26M26%

Product sales, net

$23M23%

Development milestones

$20M20%

License revenues

$5M5%

Government contract

$2M2%

Research and development services and others

$1M1%

Discounts and allowances

-$10M-10%